These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8504986)

  • 1. Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment.
    Markman M; Hakes T; Reichman B; Rubin S; Curtin J; Barakat R; Jones W; Lewis JL; Almadrones L; Hoskins W
    Gynecol Oncol; 1993 May; 49(2):185-9. PubMed ID: 8504986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.
    Markman M; Lichtman SM; Homesley H; Kennedy A; Webster K; Ernst S; Omura G; Belinson J
    Gynecol Oncol; 1998 Jul; 70(1):123-6. PubMed ID: 9698488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M
    Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE
    Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of mitoxantrone in epithelial ovarian cancer.
    Lawton F; Blackledge G; Mould J; Latief T; Watson R; Chetiyawardana AD
    Cancer Treat Rep; 1987 Jun; 71(6):627-9. PubMed ID: 3581101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration.
    Alberts DS; Surwit EA; Peng YM; McCloskey T; Rivest R; Graham V; McDonald L; Roe D
    Cancer Res; 1988 Oct; 48(20):5874-7. PubMed ID: 3167842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.
    Muggia FM; Liu PY; Alberts DS; Wallace DL; O'Toole RV; Terada KY; Franklin EW; Herrer GW; Goldberg DA; Hannigan EV
    Gynecol Oncol; 1996 Jun; 61(3):395-402. PubMed ID: 8641622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of intraperitoneal therapy for ovarian cancer.
    Markman M
    Curr Opin Obstet Gynecol; 1993 Feb; 5(1):99-104. PubMed ID: 7678757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.
    Markman M; Hakes T; Reichman B; Lewis JL; Rubin S; Jones W; Almadrones L; Hoskins W
    J Clin Oncol; 1991 Jun; 9(6):978-82. PubMed ID: 2033432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.
    Weaver CH; Greco FA; Hainsworth JD; Zhen B; Baldwin P; Wittlin F; Lewis M; West WH; Schwartzberg L; Buckner CD
    Bone Marrow Transplant; 1997 Nov; 20(10):847-53. PubMed ID: 9404925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
    Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
    Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage therapy in ovarian cancer: is there a role for intraperitoneal drug delivery?
    Markman M
    Gynecol Oncol; 1993 Oct; 51(1):86-9. PubMed ID: 8244180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal administration of Taxol in the management of ovarian cancer.
    Markman M; Rowinsky E; Hakes T; Reichman B; Jones W; Lewis JL; Rubin S; Curtin J; Barakat R; Almadrones L
    J Natl Cancer Inst Monogr; 1993; (15):103-6. PubMed ID: 7912515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
    Markman M
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):79-82. PubMed ID: 2669140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal Therapy of Ovarian Cancer.
    Markman M
    Oncologist; 1996; 1(1 & 2):18-21. PubMed ID: 10387964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.